Build an AI Virtual Tumor Board Clinical Decision-Support Platform

1. 1

   Design the human-AI team explicitly

   The defining feature is that AI treatment-effectiveness predictions are reviewed by human oncologists in a structured virtual tumor board, not delivered autonomously. As context, xDECIDE was built this way on the IRB-approved XCELSIOR pan-cancer patient registry. This deliberate augmentation design is what makes the model defensible and is why it is a distinct card from autonomous detection tools.

2. 2

   Ground the models in a compliant registry

   Credible treatment predictions require a large, well-governed clinical dataset, often an IRB-approved patient registry, that links treatments to outcomes. Data governance, consent, and IRB oversight are foundational, not optional. The registry is both the model's fuel and its ethical backbone.

3. 3

   Build treatment-effectiveness models

   The AI predicts which treatments are likely to be effective for a given patient based on the registry and the patient's data. Model quality and honest uncertainty communication matter because clinicians must trust and interrogate the output. Transparency about confidence is part of the design.

4. 4

   Operate the structured tumor board

   Real oncologists review the AI outputs and the case in a structured board format and make the recommendations, which requires clinical operations, credentialed physicians, and defined workflows. This human layer is a service business, not just software. It is also what protects the model clinically and legally.

5. 5

   Position as augmentation for liability and adoption

   Because the AI augments rather than replaces licensed oncologists, the model carries lower autonomous-diagnosis liability and gains clinician acceptance, a pattern seen across defensible high-stakes clinical AI. Make the human-in-the-loop explicit in positioning and compliance. This posture is the model's core strategic advantage.

6. 6

   Sell to providers, patients, and partners

   The service can be sold to oncology practices seeking decision support, directly to patients seeking a second opinion, or to partners, blending software and clinical-service revenue. Define the buyer and reimbursement path clearly. The human-AI hybrid augmentation model has its own adjacency card as a transferable principle.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Health-AI founders combining models with licensed clinical review

Not for: Founders chasing fully autonomous clinical AI, and anyone unwilling to staff a real licensed-oncologist review layer. The human-in-the-loop is the whole defensibility, not an obstacle to remove.